Steve Pakola is Chief Medical Officer at REGENXBIO Inc. (RGNX). They have made 3 open-market trades across 1 company since 2022, most recently 2026-08-01.
CIK 0001700659
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RGNX | 205,541 | $1.4M |
Shares reported on the most recent Form 4, priced at the 2026-08-04 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RGNX | SELL · 10b5-1 | 2026-07-02 | 2026-07-06 | $13.64 | $29K | -25.1% | -29.8% | -48.1% |
| RGNX | SELL · 10b5-1 | 2026-06-29 | 2026-07-01 | $12.23 | $689K | -9.6% | -28.8% | -45.3% |
| RGNX | SELL · 10b5-1 | 2026-05-11 | 2026-05-13 | $11.02 | $169K | -22.1% | -17.7% | +31.7% |
| RGNX | SELL | 2026-03-10 | 2026-03-12 | $10.35 | $53K | -14.0% | -0.7% | -32.5% |
| RGNX | SELL · 10b5-1 | 2024-03-05 | 2024-03-07 | $28.36 | $730K | -7.6% | -20.8% | -40.1% |
| RGNX | SELL · 10b5-1 | 2024-01-03 | 2024-01-04 | $17.39 | $600K | -17.2% | -28.0% | +18.4% |
| RGNX | SELL | 2023-01-03 | 2023-01-05 | $22.17 | $139K | +1.4% | +2.8% | -19.7% |
| RGNX | SELL | 2022-01-03 | 2022-01-04 | $33.75 | $108K | -12.0% | -22.0% | +10.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.